Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duncan Sinclair

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Schizophrenia Bulletin|October 6, 2017
Overexpression of Neuregulin 1 Type III Confers Hippocampal mRNA Alterations and Schizophrenia-Like Behaviors in MiceJuan C Olaya, Carrie L Heusner, Mitsuyuki Matsumoto, et al.
Schizophrenia Research|August 12, 2015
Molecular evidence for decreased synaptic efficacy in the postmortem olfactory bulb of individuals with schizophreniaChijioke N Egbujo, Duncan Sinclair, Karin E Borgmann-Winter, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 24, 2021
Change in modifiable dementia risk factors during COVID-19 lockdown: The experience of over 50s in Tasmania, AustraliaLarissa Bartlett, James J R Brady, Maree Farrow, et al.
Journal of Neurochemistry|November 18, 2024
Convergent effects of synthetic glucocorticoid dexamethasone and amyloid beta in human olfactory neurosphere-derived cellsZane Farnum, Radhika Mani, Aidan Bindoff, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 30, 2024
Experimental laboratory models as tools for understanding modifiable dementia riskDuncan Sinclair, Alison J Canty, Jenna M Ziebell, et al.
Frontiers in Cellular Neuroscience|May 31, 2013
Rethinking schizophrenia in the context of normal neurodevelopmentVibeke S Catts, Samantha J Fung, Leonora E Long, et al.
Clinical Therapeutics|August 6, 2010
Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phaseAllan Gordon, Denis Callaghan, Donald Spink, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Schizophrenia Bulletin|October 6, 2017
Overexpression of Neuregulin 1 Type III Confers Hippocampal mRNA Alterations and Schizophrenia-Like Behaviors in MiceJuan C Olaya, Carrie L Heusner, Mitsuyuki Matsumoto, et al.
Schizophrenia Research|August 12, 2015
Molecular evidence for decreased synaptic efficacy in the postmortem olfactory bulb of individuals with schizophreniaChijioke N Egbujo, Duncan Sinclair, Karin E Borgmann-Winter, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 24, 2021
Change in modifiable dementia risk factors during COVID-19 lockdown: The experience of over 50s in Tasmania, AustraliaLarissa Bartlett, James J R Brady, Maree Farrow, et al.
Journal of Neurochemistry|November 18, 2024
Convergent effects of synthetic glucocorticoid dexamethasone and amyloid beta in human olfactory neurosphere-derived cellsZane Farnum, Radhika Mani, Aidan Bindoff, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 30, 2024
Experimental laboratory models as tools for understanding modifiable dementia riskDuncan Sinclair, Alison J Canty, Jenna M Ziebell, et al.
Frontiers in Cellular Neuroscience|May 31, 2013
Rethinking schizophrenia in the context of normal neurodevelopmentVibeke S Catts, Samantha J Fung, Leonora E Long, et al.
Clinical Therapeutics|August 6, 2010
Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phaseAllan Gordon, Denis Callaghan, Donald Spink, et al.
Pageof 3